PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022Business Wire • 09/06/22
PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye PharmaceuticalsBusiness Wire • 08/24/22
PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in JapanBusiness Wire • 08/01/22
PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product CandidateBusiness Wire • 07/14/22
PureTech Founded Entity Akili Announces Public Company Board of Director NomineesBusiness Wire • 07/11/22
PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)Business Wire • 06/30/22
PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial ConsortiaBusiness Wire • 06/28/22
Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial ConsortiaBusiness Wire • 06/28/22
PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300Business Wire • 06/14/22
PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory ComplicationsBusiness Wire • 06/14/22
Vedanta Biosciences to Participate in the JMP Securities Life Sciences ConferenceBusiness Wire • 06/08/22
PureTech Founded Entity Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating OfficerBusiness Wire • 06/06/22
PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with RobloxBusiness Wire • 05/26/22
PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual MeetingBusiness Wire • 05/24/22
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual MeetingBusiness Wire • 05/24/22
PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022Business Wire • 05/16/22
PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022Business Wire • 05/04/22
PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New StudyBusiness Wire • 04/29/22
PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 ResultsBusiness Wire • 04/13/22
Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 ResultsBusiness Wire • 04/13/22
